Pharmaceuticals, Biotechnology and Life Sciences
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate…
– By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo- Acoramidis significantly reduced the cumulative…
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a…
ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) — The attached notification relates to trades entered into by a PDMR of…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
PALO ALTO, Calif. , Sept. 26, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an…
DENVER, Sept. 26, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial…
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the…
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney,…
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney,…